Cargando…
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group
BACKGROUND: Surgery can cure a significant percentage of ovarian carcinoma confined to the pelvis. Nevertheless, there is still a 10–50% recurrence rate. We administered paclitaxel/carboplatin as adjuvant treatment in early-stage ovarian carcinoma. METHODS: Patients with stages Ia or Ib, Grade 2 or...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592509/ https://www.ncbi.nlm.nih.gov/pubmed/16999858 http://dx.doi.org/10.1186/1471-2407-6-228 |
_version_ | 1782130410618093568 |
---|---|
author | Bamias, Aristotle Papadimitriou, Christos Efstathiou, Eleni Rodolakis, Alexandros Vlahos, Georgios Voulgaris, Zannis Bozas, Georgios Fountzilas, Georgios Aravantinos, Gerassimos Razis, Evagelia Gika, Dimitra Dimopoulos, Meletios A |
author_facet | Bamias, Aristotle Papadimitriou, Christos Efstathiou, Eleni Rodolakis, Alexandros Vlahos, Georgios Voulgaris, Zannis Bozas, Georgios Fountzilas, Georgios Aravantinos, Gerassimos Razis, Evagelia Gika, Dimitra Dimopoulos, Meletios A |
author_sort | Bamias, Aristotle |
collection | PubMed |
description | BACKGROUND: Surgery can cure a significant percentage of ovarian carcinoma confined to the pelvis. Nevertheless, there is still a 10–50% recurrence rate. We administered paclitaxel/carboplatin as adjuvant treatment in early-stage ovarian carcinoma. METHODS: Patients with stages Ia or Ib, Grade 2 or 3 and Ic to IIb (any grade) were included. Patients were treated with 4 cycles of Paclitaxel 175 mg/m(2 )and Carboplatin [area under the curve (AUC) 6 (Calvert Formula)] every 3 weeks. RESULTS: Sixty-nine patients with no residual disease following cytoreductive surgery and minimal or modified surgical staging were included in this analysis. Grade 3 or 4 neutropenia occured in 29.9% of patients, while neutropenic fever was reported in 4.5%. Neurotoxicity (all Grade 1 or 2) was reported in 50% of cases. Median follow-up was 62 months. 5-year overall survival (OS) and relapse-free survival (RFS) were: 87% (95% confidence intervals [CI]: 78–96) and 79% (95% CI: 69–89), respectively. Significantly fewer patients with stages Ic-IIb and tumor grade 2 or 3 achieved a 5-year RFS than patients with only one of these two factors (73% vs 92%, p = 0.03). CONCLUSION: Paclitaxel/Carboplatin chemotherapy is a safe and effective adjuvant treatment in early-stage ovarian carcinoma. Patients with stages Ic-IIb and tumor grade 2 or 3 may benefit from more extensive treatment. |
format | Text |
id | pubmed-1592509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-15925092006-10-07 Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group Bamias, Aristotle Papadimitriou, Christos Efstathiou, Eleni Rodolakis, Alexandros Vlahos, Georgios Voulgaris, Zannis Bozas, Georgios Fountzilas, Georgios Aravantinos, Gerassimos Razis, Evagelia Gika, Dimitra Dimopoulos, Meletios A BMC Cancer Research Article BACKGROUND: Surgery can cure a significant percentage of ovarian carcinoma confined to the pelvis. Nevertheless, there is still a 10–50% recurrence rate. We administered paclitaxel/carboplatin as adjuvant treatment in early-stage ovarian carcinoma. METHODS: Patients with stages Ia or Ib, Grade 2 or 3 and Ic to IIb (any grade) were included. Patients were treated with 4 cycles of Paclitaxel 175 mg/m(2 )and Carboplatin [area under the curve (AUC) 6 (Calvert Formula)] every 3 weeks. RESULTS: Sixty-nine patients with no residual disease following cytoreductive surgery and minimal or modified surgical staging were included in this analysis. Grade 3 or 4 neutropenia occured in 29.9% of patients, while neutropenic fever was reported in 4.5%. Neurotoxicity (all Grade 1 or 2) was reported in 50% of cases. Median follow-up was 62 months. 5-year overall survival (OS) and relapse-free survival (RFS) were: 87% (95% confidence intervals [CI]: 78–96) and 79% (95% CI: 69–89), respectively. Significantly fewer patients with stages Ic-IIb and tumor grade 2 or 3 achieved a 5-year RFS than patients with only one of these two factors (73% vs 92%, p = 0.03). CONCLUSION: Paclitaxel/Carboplatin chemotherapy is a safe and effective adjuvant treatment in early-stage ovarian carcinoma. Patients with stages Ic-IIb and tumor grade 2 or 3 may benefit from more extensive treatment. BioMed Central 2006-09-25 /pmc/articles/PMC1592509/ /pubmed/16999858 http://dx.doi.org/10.1186/1471-2407-6-228 Text en Copyright © 2006 Bamias et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bamias, Aristotle Papadimitriou, Christos Efstathiou, Eleni Rodolakis, Alexandros Vlahos, Georgios Voulgaris, Zannis Bozas, Georgios Fountzilas, Georgios Aravantinos, Gerassimos Razis, Evagelia Gika, Dimitra Dimopoulos, Meletios A Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group |
title | Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group |
title_full | Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group |
title_fullStr | Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group |
title_full_unstemmed | Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group |
title_short | Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group |
title_sort | four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the hellenic cooperative oncology group |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592509/ https://www.ncbi.nlm.nih.gov/pubmed/16999858 http://dx.doi.org/10.1186/1471-2407-6-228 |
work_keys_str_mv | AT bamiasaristotle fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup AT papadimitriouchristos fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup AT efstathioueleni fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup AT rodolakisalexandros fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup AT vlahosgeorgios fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup AT voulgariszannis fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup AT bozasgeorgios fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup AT fountzilasgeorgios fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup AT aravantinosgerassimos fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup AT razisevagelia fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup AT gikadimitra fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup AT dimopoulosmeletiosa fourcyclesofpaclitaxelandcarboplatinasadjuvanttreatmentinearlystageovariancancerasixyearexperienceofthehelleniccooperativeoncologygroup |